Multivariate Cox regression analysis of predictors of mortality among COPD population
| B | SE | Df | Sig. | HR | 95% CI for HR | ||
| Lower | Upper | ||||||
| Age | 0.088 | 0.077 | 1 | 0.253 | 1.09 | 0.94 | 1.27 |
| Basal mMRC dyspnoea scale | 0.348 | 0.102 | 1 | 0.001* | 1.42 | 1.16 | 1.73 |
| FEV1% predicted | −0.097 | 0.081 | 1 | 0.231 | 0.91 | 0.78 | 1.06 |
| Pseudomonas aeruginosa infection | 0.464 | 0.165 | 1 | 0.005* | 1.59 | 1.15 | 2.20 |
| Blood eosinophils ≥300 cells/uL | −0.340 | 0.166 | 1 | 0.040* | 0.71 | 0.52 | 0.99 |
| ICS use | −0.593 | 0.435 | 1 | 0.172 | 0.55 | 0.24 | 1.30 |
| ICS dose† | 0.283 | 0.110 | 1 | 0.010* | 1.33 | 1.07 | 1.65 |
*Significant p≤0.05.
†Fluticasone propionate equivalents (daily dose).
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; mMRC, modified medical research council.